Dey Subo, Frishman William H, Aronow Wilbert S
From the Departments of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Departments of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY.
Cardiol Rev. 2025;33(3):243-245. doi: 10.1097/CRD.0000000000000595. Epub 2023 Aug 7.
Systemic hypertension remains one of the leading cause of morbidity and mortality in the United States and throughout the world. Baxdrostat (CIN-107), a new drug developed by Roche is a selective aldosterone synthase inhibitor that is being evaluated as one of the potential treatments for hypertension, especially in patients with drug treatment-resistant hypertension. An increased level of aldosterone is associated with inflammation, systemic hypertension, and organ fibrosis, contributing to adverse cardiovascular events. A phase 2 trial, BrigHTN, showed promising results in demonstrating the efficacy of baxdrostat, where The HALO (efficacy and safety of baxdrostat in patients with uncontrolled hypertension) trial did not demonstrate any blood pressure-lowering benefit of baxdrostat when compared with the placebo. Several additional studies are now underway to evaluate the effectiveness of baxdrostat as an anti-hypertensive agent.
系统性高血压仍然是美国乃至全世界发病和死亡的主要原因之一。巴多司他（CIN-107）是罗氏公司研发的一种新药，是一种选择性醛固酮合酶抑制剂，正作为高血压的潜在治疗方法之一进行评估，尤其是对药物治疗抵抗性高血压患者。醛固酮水平升高与炎症、系统性高血压和器官纤维化有关，会导致不良心血管事件。一项2期试验BrigHTN在证明巴多司他的疗效方面显示出有希望的结果，而HALO（巴多司他在未控制高血压患者中的疗效和安全性）试验与安慰剂相比未显示出巴多司他有任何降压益处。目前正在进行几项额外研究，以评估巴多司他作为抗高血压药物的有效性。
